Your browser doesn't support javascript.
loading
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Richard, Shambavi; Chari, Ajai; Delimpasi, Sosana; Simonova, Maryana; Spicka, Ivan; Pour, Ludek; Kriachok, Iryna; Dimopoulos, Meletios A; Pylypenko, Halyna; Auner, Holger W; Leleu, Xavier; Usenko, Ganna; Hajek, Roman; Benjamin, Reuben; Dolai, Tuphan Kanti; Sinha, Dinesh Kumar; Venner, Christopher P; Garg, Mamta; Stevens, Don Ambrose; Quach, Hang; Jagannath, Sundar; Moreau, Phillipe; Levy, Moshe; Badros, Ashraf; Anderson, Larry D; Bahlis, Nizar J; Facon, Thierry; Mateos, Maria Victoria; Cavo, Michele; Chang, Hua; Landesman, Yosef; Chai, Yi; Arazy, Melina; Shah, Jatin; Shacham, Sharon; Kauffman, Michael G; Grosicki, Sebastian; Richardson, Paul G.
Affiliation
  • Richard S; Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA.
  • Chari A; Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA.
  • Delimpasi S; General Hospital Evangelismos, Athens, Greece.
  • Simonova M; Institute of Blood Pathology & Transfusion Medicine of National Academy of Medical Sciences of Ukraine, Lviv, Ukraine.
  • Spicka I; Charles University and General Hospital, Prague, Czech Republic.
  • Pour L; Clinic of Internal Medicine -Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Kriachok I; National Cancer Institute Ukraine, Kiev, Ukraine.
  • Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Pylypenko H; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.
  • Auner HW; Imperial College London, London, UK.
  • Leleu X; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.
  • Usenko G; City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine.
  • Hajek R; Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
  • Benjamin R; Kings College Hospital NHS Foundation Trust, London, UK.
  • Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India.
  • Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.
  • Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Stevens DA; Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, USA.
  • Quach H; University of Melbourne, St. Vincent's Hospital, Melbourne, Victoria, Australia.
  • Jagannath S; Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA.
  • Moreau P; University Hospital, Hotel-Dieu, Nantes, France.
  • Levy M; Baylor University Medical Center, Dallas, Texas, USA.
  • Badros A; University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Anderson LD; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Bahlis NJ; University of Calgary, Charbonneau Cancer Research Institute, Calgary, Alberta, Canada.
  • Facon T; CHU Lille Service des Maladies du Sang F-59000, Lille, France.
  • Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain.
  • Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Chang H; Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
  • Landesman Y; Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
  • Chai Y; Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
  • Arazy M; Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
  • Shah J; Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
  • Shacham S; Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
  • Kauffman MG; Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
  • Grosicki S; Medical University of Silesia, Katowice, Poland.
  • Richardson PG; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Am J Hematol ; 96(9): 1120-1130, 2021 09 01.
Article in En | MEDLINE | ID: mdl-34062004
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Dexamethasone / Bortezomib / Hydrazines / Multiple Myeloma / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Hematol Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Dexamethasone / Bortezomib / Hydrazines / Multiple Myeloma / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Hematol Year: 2021 Document type: Article Affiliation country: Country of publication: